MarketCapExport financials
Schrödinger (SDGR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Schrödinger Income Statement 2025-2011 | SDGR
Brief overview of revenue and earnings at Schrödinger
This overview is based on financial performance over the past five years. Schrödinger reported revenue of 108 million dollars in 2020 and 256 million dollars by 2025. Across the full period, sales moved by +136.7%; the average annual rate was 18.8%. Top-line growth remained consistently strong over the period.
At the gross-profit level, the result moved from $63.5 million to $143 million, a change of +124.7%. The cost base moved against the top-line trend and weighed on the gross result. Gross profit as a share of revenue changed from 58.7% to 55.7%. A lower margin indicates deterioration in the economics of the core business.
Over the period, EBITDA shifted from −57.3 million dollars to −161 million dollars, a change of −181%. EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin was −53% at the start and −62.9% at the end. Operating return per unit of revenue declined.
Across the five years, the net result shifted from −$24.5 million to −$103 million. The period ended with a larger loss than it began with.
Over the period, capitalization shifted from $5.4 billion to $867 million (−84%). Investors remain cautious despite better financial results.
Financial takeaway
The current trajectory does not yet confirm a sustainable recovery. The financial profile benefits from revenue expansion. The main areas of concern are lower investor confidence, declining net profitability and pressure from direct costs. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Schrödinger
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
867 M | 1.56 B | 2.27 B | 1.54 B | 2 B | 5.42 B | - | - | - | - | - | - | - | - | - |
Shares |
73.4 M | 72.7 M | 71.8 M | 71.2 M | 70.6 M | 60 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
11.8 | 21.5 | 31.6 | 21.7 | 28.4 | 90.3 | - | - | - | - | - | - | - | - | - |
Net Income |
-103 M | -187 M | 40.7 M | -149 M | -101 M | -24.5 M | -24.6 M | -28.4 M | -17.4 M | - | - | - | - | - | - |
Revenue |
256 M | 208 M | 217 M | 181 M | 138 M | 108 M | 85.5 M | 66.6 M | 55.7 M | - | - | - | - | - | - |
Cost of Revenue |
113 M | 75.5 M | 76 M | 79.9 M | 72.3 M | 44.6 M | 36.4 M | - | - | - | - | - | - | - | - |
Gross Profit |
143 M | 132 M | 141 M | 101 M | 65.6 M | 63.5 M | 49.1 M | 42.9 M | 39.8 M | - | - | - | - | - | - |
Operating Income |
-167 M | -209 M | -177 M | -147 M | -111 M | -60.9 M | -38.7 M | - | - | - | - | - | - | - | - |
Interest Expense |
16.4 M | 17.9 M | 19.7 M | 3.95 M | 1.06 M | 2.25 M | - | - | - | - | - | - | - | - | - |
EBITDA |
-161 M | -203 M | -172 M | -142 M | -109 M | -57.3 M | -35.1 M | -25.1 M | -17.3 M | - | - | - | - | - | - |
Operating Expenses |
310 M | 341 M | 318 M | 248 M | 177 M | 124 M | 87.8 M | 70.9 M | 58.8 M | - | - | - | - | - | - |
General and Administrative Expenses |
95.4 M | 99.7 M | 99.1 M | 90.8 M | 64 M | 41.9 M | 27 M | 18.6 M | 14.4 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Schrödinger
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
74.9 M | 74.7 M | 74 M | 75.1 M | 73.6 M | 73.4 M | 73.1 M | 64.3 M | 72.8 M | 72.7 M | 72.3 M | 96.5 M | 71.9 M | 71.6 M | 71.5 M | 32.7 M | 71.2 M | 71.2 M | 71.1 M | -141 M | 70.8 M | 70.6 M | 70.1 M | -110 M | 66.3 M | 63.3 M | 40.7 M | 6.12 M | 44.9 M | 44.5 M | 5.94 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-37.7 M | 5.98 M | -60 M | 32.5 M | -32.8 M | -43.2 M | -59.8 M | -40.2 M | -38.1 M | -54 M | -54.7 M | -30.7 M | -62 M | 4.28 M | 129 M | -27.2 M | -39.9 M | -47.7 M | -34.4 M | -30.7 M | -35 M | -35 M | -523 K | -11.6 M | 3.29 M | -4.07 M | -14.3 M | - | -11.5 M | -500 K | -5.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
64.5 M | 58.9 M | 58.6 M | 87.2 M | 54.3 M | 54.8 M | 59.6 M | 88.3 M | 35.3 M | 47.3 M | 36.6 M | 74.1 M | 42.6 M | 35.2 M | 64.8 M | 56.8 M | 37 M | 38.5 M | 48.7 M | 46.2 M | 29.8 M | 29.8 M | 32.1 M | 33 M | 25.8 M | 23.1 M | 26.2 M | - | 20 M | 19 M | 20.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
26.2 M | 26.5 M | 29 M | 29.9 M | 26.3 M | 28.6 M | 28.4 M | 24.2 M | 17.6 M | 16 M | 17.7 M | 16.6 M | 18.9 M | 21.4 M | 19.1 M | 18.1 M | 19.8 M | 21.3 M | 20.7 M | 19.8 M | 18.7 M | 17.8 M | 16 M | 14 M | 10.5 M | 9.51 M | 10.5 M | - | 9.25 M | 9.16 M | 7.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
38.3 M | 32.4 M | 29.5 M | 57.3 M | 28 M | 26.2 M | 31.1 M | 64.1 M | 17.7 M | 31.3 M | 18.9 M | 57.6 M | 23.6 M | 13.8 M | 45.7 M | 38.7 M | 17.2 M | 17.1 M | 28 M | 26.4 M | 11.1 M | 12 M | 16.2 M | 19 M | 15.3 M | 13.6 M | 15.6 M | - | 10.7 M | 9.85 M | 13 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-26.1 M | -41.5 M | -48.8 M | -17.2 M | -45.9 M | -52.9 M | -50.9 M | -20.7 M | -68.4 M | -52.7 M | -67.4 M | -29.6 M | -56.2 M | -61.1 M | -30.5 M | -28.5 M | -46.2 M | -43.5 M | -28.6 M | -22.5 M | -34.7 M | -30.3 M | -23.9 M | -16.6 M | -15.4 M | -17.1 M | -11.8 M | - | -11.3 M | -14 M | -5.61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
3.33 M | 3.03 M | 2.66 M | 3.13 M | 3.62 M | 5.44 M | 4.2 M | 3.54 M | 4.74 M | 4.6 M | 5.03 M | 6.63 M | 5.8 M | 4.33 M | 2.94 M | 2.69 M | 1.23 M | -308 K | 339 K | -6 K | 286 K | 357 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-26.1 M | -40.1 M | -47.3 M | -15.7 M | -44.5 M | -51.4 M | -49.3 M | -18.9 M | -66.9 M | -51.3 M | -66 M | -33.2 M | -54.9 M | -60 M | -28.7 M | -31.2 M | -45.1 M | -42.3 M | -27.7 M | -24.7 M | -34.1 M | -29.6 M | -23 M | -15.6 M | -14.6 M | -16.2 M | -10.9 M | - | -8.56 M | -12.2 M | -4.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
64.4 M | 74 M | 78.3 M | 74.4 M | 74 M | 79.1 M | 82 M | 84.8 M | 86.2 M | 84.1 M | 86.3 M | 87.2 M | 79.8 M | 74.9 M | 76.2 M | 67.2 M | 63.4 M | 60.6 M | 56.6 M | 48.9 M | 45.8 M | 42.3 M | 40.1 M | 35.6 M | 30.7 M | 30.7 M | 27.4 M | - | 22 M | 23.8 M | 18.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
20.3 M | 22.7 M | 22.9 M | 22.7 M | 21.7 M | 25.2 M | 25.8 M | 25.8 M | 24.8 M | 23.5 M | 25.5 M | 25.7 M | 23.9 M | 23.2 M | 26.3 M | 23.3 M | 23.3 M | 22.1 M | 22.1 M | 17.8 M | 17 M | 15.8 M | 13.4 M | 13.6 M | 9.73 M | 9.65 M | 8.94 M | - | 6.46 M | 8.94 M | 5.09 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Schrödinger (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B |  USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.34 | -1.37 % | $ 173 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
10x Genomics
TXG
|
$ 62.88 | -3.34 % | $ 7.84 B | USA |
 |
Veeva Systems
VEEV
|
$ 306.1 | -0.1 % | $ 50.1 B | USA |
 |
SCWorx Corp.
WORX
|
$ 1.31 | -5.76 % | $ 9.53 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.94 | -5.99 % | $ 3.21 M |  China |
 |
HealthStream
HSTM
|
$ 28.69 | -0.14 % | $ 861 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
So-Young International
SY
|
$ 2.0 | 0.5 % | $ 156 M | China |
 |
American Well Corporation
AMWL
|
$ 12.0 | -3.73 % | $ 193 M | USA |
 |
Evolent Health
EVH
|
$ 4.79 | 1.7 % | $ 547 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.54 | -3.01 % | $ 1.26 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.46 | -3.31 % | $ 102 M | USA |
 |
HealthEquity
HQY
|
$ 103.68 | 1.53 % | $ 8.93 B | USA |
 |
Omnicell
OMCL
|
$ 35.87 | -3.96 % | $ 1.65 B | USA |
 |
Progyny
PGNY
|
$ 36.44 | 1.35 % | $ 3.11 B | USA |
 |
Teladoc Health
TDOC
|
$ 8.96 | -0.28 % | $ 1.58 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Phreesia
PHR
|
$ 13.15 | 1.94 % | $ 786 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |